Akari Therapeutics Plc Bennfentes tulajdonlás

Mi az Akari Therapeutics Plc Bennfentes tulajdonlás?

A Bennfentes tulajdonlás az Akari Therapeutics Plc - 4.89%

Mi a Bennfentes tulajdonlás meghatározása?

A bennfentes tulajdonjog kiszámítása a bennfentesek tulajdonában lévő részvények (részvényesek, akik a vállalat több mint 5% -át, vagy a vállalat tisztségviselőjét vagy igazgatóját birtokolják) teljes létszámával, osztva a teljes részvénykivonással.

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

Mit csinál Akari Therapeutics Plc?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

bennfentes tulajdonlás -hoz hasonló cégek Akari Therapeutics Plc